Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Missouri City, TX 77459, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
55
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
The National Cancer Institute awarded a definitive firm fixed-price contract to Tenaci-T Therapeutics LLC for $297,621 on September 17, 2025, under a total small business set-aside. The award is an FY2025 SBIR Concept Clearance Award for development of therapeutic or preventative technologies for treatment or prevention of pediatric cancers and/or rare cancers, specifically targeting FOXM1 in glioblastoma multiforme using a novel TCR-T cell therapeutic.
The originating solicitation, posted March 28, 2024, sought proposals from small business concerns for innovative and transformative technologies in therapeutic or preventative approaches, devices, diagnostics, or digital health tools addressing pediatric and rare cancers. Proposals were required to identify an anticipated product, clinical problem, and cancer type(s) to be addressed, provide initial proof-of-concept data, and develop a business model and commercialization plan. Place of performance is Missouri City, TX. The contract period extends to September 16, 2027.